Many endocrinologists view semaglutide as appropriate for lifelong use given obesity is a chronic condition
It means either the dose is wrong, the compound doesnt work for you, the product quality is poor, or the effect size is below what you can detect subjectively
GHRPs are short-chain peptides designed to stimulate the pituitary gland , prompting the natural release of growth hormone (GH)
Get back to your regular schedule
The SUSTAIN and STEP trial series for semaglutide demonstrated 1015% body weight reduction over 68 weeks in the STEP 1 trial (Wilding et al., 2021, NEJM: The SURMOUNT-1 trial for tirzepatide demonstrated up to 20.9% weight reduction at the highest dose (Jastreboff et al., 2022, NEJM: Retatrutide Phase II data (Jastreboff et al., 2023, NEJM) showed up to 24.2% weight loss, the highest reported for any pharmacological intervention in a randomised trial at the time of publication
These products aim to reduce hyperpigmentation and improve skin texture